Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia, Evripidis Gavathiotis, Poulikos I. Poulikakos
Nature reviews. Cancer (2017) Vol. 17, Iss. 11, pp. 676-691
Open Access | Times Cited: 342

Showing 1-25 of 342 citing articles:

Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen, Darren A.E. Cross, Pasi A. Jänne
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 7, pp. 551-569
Open Access | Times Cited: 777
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Shannon Lee, Jens Rauch, Walter Kölch
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 1102-1102
Open Access | Times Cited: 635
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan, Ferran Fece de la Cruz, Sarah Phat, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 7, pp. 1633-1643
Open Access | Times Cited: 372
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao, Yonina R. Murciano‐Goroff, Jenny Y. Xue, et al.
Nature (2021) Vol. 599, Iss. 7886, pp. 679-683
Open Access | Times Cited: 313
RAF-MEK-ERK pathway in cancer evolution and treatment
Rahim Ullah, Qing Yin, Aidan Snell, et al.
Seminars in Cancer Biology (2021) Vol. 85, pp. 123-154
Closed Access | Times Cited: 287
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
Eunyoung Park, Shaun Rawson, Kunhua Li, et al.
Nature (2019) Vol. 575, Iss. 7783, pp. 545-550
Open Access | Times Cited: 267
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Md Entaz Bahar, Hyun Joon Kim, Deok Ryong Kim
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 231
Many ways to resistance: How melanoma cells evade targeted therapies
Ines Kozar, Christiane Margue, Sonja Rothengatter, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2019) Vol. 1871, Iss. 2, pp. 313-322
Open Access | Times Cited: 224
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 224
Codon-specific translation reprogramming promotes resistance to targeted therapy
Francesca Rapino, Sylvain Delaunay, Florian Rambow, et al.
Nature (2018) Vol. 558, Iss. 7711, pp. 605-609
Closed Access | Times Cited: 219
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Hyuk Moon, Simon Weonsang Ro
Cancers (2021) Vol. 13, Iss. 12, pp. 3026-3026
Open Access | Times Cited: 198
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Mylène Tajan, Romain Paccoud, Sophie Branka, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 676-700
Open Access | Times Cited: 195
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas Eigentler, Michael Fluck, et al.
ESMO Open (2019) Vol. 4, Iss. 3, pp. e000491-e000491
Open Access | Times Cited: 185
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
Tamer A. Ahmed, Christos Adamopoulos, Zoi Karoulia, et al.
Cell Reports (2019) Vol. 26, Iss. 1, pp. 65-78.e5
Open Access | Times Cited: 182
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Dong-Sung Kim, Jenny Y. Xue, Piro Lito
Cell (2020) Vol. 183, Iss. 4, pp. 850-859
Open Access | Times Cited: 174
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Robert Roskoski
Pharmacological Research (2018) Vol. 135, pp. 239-258
Closed Access | Times Cited: 173
Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy
Peijie Zheng, Chuntao Zhou, Liuyi Lu, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 171
Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 160
Targeting the ERK Signaling Pathway in Melanoma
Paola Savoia, Paolo Fava, Filippo Casoni, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 6, pp. 1483-1483
Open Access | Times Cited: 151
Initiation and amplification of SnRK2 activation in abscisic acid signaling
Zhen Lin, Yuan Li, Yubei Wang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 150
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
Pankaj Sharma, Chris LaRosa, Janet Antwi, et al.
Molecules (2021) Vol. 26, Iss. 14, pp. 4213-4213
Open Access | Times Cited: 126
Understanding and targeting resistance mechanisms in cancer
Zi‐Ning Lei, Tian Qin, Qiu‐Xu Teng, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 107
Mutant-selective degradation by BRAF-targeting PROTACs
Shanique Alabi, Saul Jaime‐Figueroa, Zhan Yao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 103
Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors
Christopher Arter, Luke Trask, Sarah Ward, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 8, pp. 102247-102247
Open Access | Times Cited: 101
Page 1 - Next Page

Scroll to top